인간 배아줄기세포 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the human embryonic stem cells market size was valued at USD 1.22 billion in 2025 and is estimated to grow from USD 1.33 billion in 2026 to reach USD 2.05 billion by 2031, at a CAGR of 9.05% during the forecast period (2026-2031).

This report is Segmented by Application (Regenerative Medicine, Stem-Cell Biology Research, Tissue Engineering, Toxicology Testing), Product Type (hESC Lines, Culture Media & Reagents, Instruments & Consumables), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Human Embryonic Stem Cells Market Trends and Insights

High Prevalence of Cardiac and Malignant Diseases

Cardiovascular disorders and cancer together account for the majority of mortality worldwide, creating sustained clinical demand for multi-lineage repair solutions. Human embryonic stem-cell-derived cardiac spheroids restore contractility in porcine infarct models and are now entering first-in-human ischemic cardiomyopathy trials. hESC-derived islet cells (VX-880) achieved insulin independence in 10 of 12 type 1 diabetes patients, underscoring the breadth of application potential. Commercial interest intensifies as population-level spending on cardiac care exceeds USD 350 billion, positioning cardiometabolic programs as headline value drivers within the human embryonic stem cells market. Additive-manufacturing breakthroughs, such as 3-D-printed myocardium scaffolds seeded with hESCs, further shorten translational pathways. Collectively, these data validate disease-modifying potential and reinforce premium pricing opportunities through 2030.

Rising Demand for Regenerative Medicine

More than 1,200 active cell and gene therapy trials in the United States showcase how regenerative medicine is moving from fringe to frontline care. Allogeneic platforms that rely on human embryonic stem cells enable off-the-shelf dosing, solving historical scale limitations of autologous procedures. Japan's 60-plus iPS cell studies illustrate how cohesive policy, reimbursement clarity, and manufacturing incentives foster accelerated adoption. The FDA's landmark approval of a mesenchymal stromal cell therapy signals regulator readiness to clear clinically validated products, indirectly benefiting hESC developers. Vision-restoration successes using hESC-derived corneal epithelium (>=90% efficacy) elevate public trust, fueling positive feedback loops for patient recruitment and investor inflows.

High Treatment and Production Cost

Current hESC-based therapies often exceed USD 100,000 per dose, driven by manual clean-room operations and low process yields. AI-guided robotics slash labor inputs by 50% and deliver lot-to-lot consistency, pointing to breakeven manufacturing at sub-USD 50,000 within five years. Thermo Fisher's USD 475 million CDMO site in New Jersey exemplifies industry-scale investment targeting cost compression and regulatory compliance. Modular robotic clusters reproducibly handle expansion, harvesting, and final fill-finish, shortening campaign times and reducing batch failure risk. Predictive AI models from Northeastern University further optimize nutrient feeds and passage timing, pushing yields toward industrial benchmarks. These gains must sustain momentum to offset payer scrutiny and price-sensitive emerging-market demand.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Government and Private Funding Programs
2. CRISPR-Enabled hESC Line Engineering
3. Stringent and Heterogeneous Global Regulations

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Regenerative medicine captured 58.02% of the human embryonic stem cells market share in 2025, buoyed by clinical readouts such as +5.5-letter visual-acuity gains for OpRegen in geographic atrophy patients. Spinal cord repair, pancreatic islet replacement, and cardiac remuscularization now headline multi-center trials, reinforcing the segment's dominant revenue trajectory. As more programs secure RMAT or Sakigake designations, payers gain real-world evidence to justify reimbursement, fueling a virtuous adoption cycle within the human embryonic stem cells market.

Stem-cell biology research, registering a 10.45% CAGR to 2031, benefits from automated genome-editing screens and organoid platforms capable of recapitulating human tissue complexity. CRISPR-powered lineage-tracing and high-content phenomics shorten target-identification timelines, while novel organoid co-culture systems elevate disease-model accuracy five-fold. As academic core facilities transition to fee-for-service models, research spending funnels back into reagents and line-licensing royalties, enlarging recurring-revenue pools for supply-chain participants. The human embryonic stem cells market size for discovery applications is projected to climb steadily as multiplex screens become integral to precision-medicine pipelines.

Complete Report Scope:

• By Application
  • Regenerative Medicine
  • Stem-Cell Biology Research
  • Tissue Engineering
  • Toxicology Testing
• By Product Type
  • hESC Lines
  • Culture Media & Reagents
  • Instruments & Consumables
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • APAC
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA

Geography Analysis

North America retained 41.74% of global revenue in 2025, anchored by robust NIH and CIRM funding, RMAT-enabled fast-track reviews, and extensive CDMO capacity. Stanford-led cardiac trials, Northwestern's spinal cord initiatives, and Thermo Fisher's new Princeton site collectively exhibit the region's lab-to-launch integration. Political uncertainty around federal funding for embryonic research poses a strategic risk, but diversified private investment cushions potential public-budget fluctuations.

Asia-Pacific is the fastest-growing cluster, advancing at an 10.98% CAGR through 2031 on the back of Japan's conditional-approval regime and China's state-backed research parks. Over 60 active Japanese clinical trials highlight regulatory agility, while Sumitomo Pharma and Nikon-Lonza manufacturing alliances demonstrate capital inflows from multinational partners. Government grants cover facility build-outs and workforce training, amplifying local supply-chain maturity within the human embryonic stem cells market.

Europe's outlook hinges on effective rollout of the SoHO regulation in 2027. Germany and the United Kingdom maintain leading academic clusters; the UK's code of practice for synthetic embryos signals policy innovation that may shape continental standards. France and Italy focus on ophthalmology and cartilage repair niches, while Scandinavian consortia invest in cryogenic logistics to widen patient access. Western European reimbursement hurdles persist, but cross-border collaboration and EU-wide HTA reforms are expected to streamline market access for certified products.

1. Astellas Pharma
2. Thermo Fisher Scientific
3. Merck
4. Stem Cell Technologies
5. Takara Bio
6. Lineage Cell Therapeutics
7. PeproTech
8. PromoCell
9. Vertex Pharmaceuticals
10. Lonza Group
11. BD Biosciences
12. GE Healthcare
13. ViaCyte Inc.
14. Fate Therapeutics
15. BlueRock Therapeutics
16. Cynata Therapeutics
17. Pluri Inc.
18. Organovo
19. Samsung Group
20. Cell Engineering Corp.
21. Janssen (Cell Therapy Grp)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 High prevalence of cardiac & malignant diseases
  • 4.2.2 Rising demand for regenerative medicine
  • 4.2.3 Growing government & private funding programs
  • 4.2.4 CRISPR-enabled hESC line engineering
  • 4.2.5 Xeno-free GMP culture systems lower contamination risk
  • 4.2.6 Surplus IVF embryos expanding ethical hESC supply
• 4.3 Market Restraints
  • 4.3.1 High treatment & production cost
  • 4.3.2 Stringent & heterogeneous global regulations
  • 4.3.3 Fast-growing iPSC alternatives cannibalise funding
  • 4.3.4 Social-media-driven ethical activism dampens adoption
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value - USD)

• 5.1 By Application
  • 5.1.1 Regenerative Medicine
  • 5.1.2 Stem-Cell Biology Research
  • 5.1.3 Tissue Engineering
  • 5.1.4 Toxicology Testing
• 5.2 By Product Type
  • 5.2.1 hESC Lines
  • 5.2.2 Culture Media & Reagents
  • 5.2.3 Instruments & Consumables
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 South America
    • 5.3.2.1 Brazil
    • 5.3.2.2 Argentina
    • 5.3.2.3 Rest of South America
  • 5.3.3 Europe
    • 5.3.3.1 Germany
    • 5.3.3.2 United Kingdom
    • 5.3.3.3 France
    • 5.3.3.4 Italy
    • 5.3.3.5 Spain
    • 5.3.3.6 Rest of Europe
  • 5.3.4 APAC
    • 5.3.4.1 China
    • 5.3.4.2 Japan
    • 5.3.4.3 India
    • 5.3.4.4 Australia
    • 5.3.4.5 South Korea
    • 5.3.4.6 Rest of APAC
  • 5.3.5 Middle East & Africa
    • 5.3.5.1 GCC
    • 5.3.5.2 South Africa
    • 5.3.5.3 Rest of MEA

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.4.1 Astellas Pharma Inc.
  • 6.4.2 Thermo Fisher Scientific Inc.
  • 6.4.3 Merck KGaA
  • 6.4.4 STEMCELL Technologies Inc.
  • 6.4.5 Takara Bio Inc.
  • 6.4.6 Lineage Cell Therapeutics Inc.
  • 6.4.7 PeproTech Inc.
  • 6.4.8 PromoCell GmbH
  • 6.4.9 Vertex Pharmaceuticals
  • 6.4.10 Lonza Group AG
  • 6.4.11 BD Biosciences
  • 6.4.12 GE HealthCare
  • 6.4.13 ViaCyte Inc.
  • 6.4.14 Fate Therapeutics
  • 6.4.15 BlueRock Therapeutics
  • 6.4.16 Cynata Therapeutics
  • 6.4.17 Pluri Inc.
  • 6.4.18 Organovo Holdings Inc.
  • 6.4.19 Samsung Biologics
  • 6.4.20 Cell Engineering Corp.
  • 6.4.21 Janssen (Cell Therapy Grp)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment